Prelude Therapeutics Inc — Director's Dealing 2022

Jun 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Prelude Therapeutics Inc (PRLD)
CIK: 0001678660
Period of Report: 2022-06-17

Reporting Person: Babler Martin (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-17	Director Stock Option (Right to Buy)	$4.74	A	31293.00	Acquired	2032-06-16	Common Stock (31293.00)	Direct

Footnotes

F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.